|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Morrison J: Advances in the understanding
and treatment of ovarian cancer. J Br Menopause Soc. 11:66–71.
2005. View Article : Google Scholar
|
|
3
|
Munkarah A, Chatterjee M and Tainsky MA:
Update on ovarian cancer screening. Curr Opin Obstet Gynecol.
19:22–26. 2007. View Article : Google Scholar
|
|
4
|
McGuire WP III and Markman M: Primary
ovarian cancer chemotherapy: current standards of care. Br J
Cancer. 89(Suppl): S3–S8. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bristow RE and Chi DS: Platinum-based
neoadjuvant chemotherapy and interval surgical cytoreduction for
advanced ovarian cancer: a meta-analysis. Gynecol Oncol.
103:1070–1076. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kelland LR: Emerging drugs for ovarian
cancer. Expert Opin Emerg Drugs. 10:413–424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harries M and Gore M: Part II:
chemotherapy for epithelial ovarian cancer-treatment of recurrent
disease. Lancet Oncol. 3:537–545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harries M and Gore M: Part I: chemotherapy
for epithelial ovarian cancer-treatment at first diagnosis. Lancet
Oncol. 3:529–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jansen BA, Brouwer J and Reedijk J:
Glutathione induces cellular resistance against cationic dinuclear
platinum anticancer drugs. J Inorg Biochem. 89:197–202. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi KC, Auersperg N and Leung PC:
Mitogen-activated protein kinases in normal and (pre)neoplastic
ovarian surface epithelium. Reprod Biol Endocrinol. 1:712003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mabuchi S, Ohmichi M, Nishio Y, et al:
Inhibition of NFkappaB increases the efficacy of cisplatin in in
vitro and in vivo ovarian cancer models. J Biol Chem.
279:23477–23485. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rudin CM, Yang Z, Schumaker LM, et al:
Inhibition of glutathione synthesis reverses Bcl-2-mediated
cisplatin resistance. Cancer Res. 63:312–318. 2003.PubMed/NCBI
|
|
15
|
Miyazaki Y, Shibuya M, Sugawara H,
Kawaguchi O and Hirsoe C: Salinomycin, a new polyether antibiotic.
J Antibiot. 27:814–821. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Callaway TR, Edrington TS, Rychlik JL, et
al: Ionophores: their use as ruminant growth promotants and impact
on food safety. Curr Issues Intest Microbiol. 4:43–51.
2003.PubMed/NCBI
|
|
17
|
Gupta PB, Onder TT, Jiang G, et al:
Identification of selective inhibitors of cancer stem cells by
high-throughput screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fuchs D, Heinold A, Opelz G, Daniel V and
Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis
resistance in human cancer cells. Biochem Biophys Res Commun.
390:743–749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fuchs D, Daniel V, Sadeghi M, Opelz G and
Naujokat C: Salinomycin overcomes ABC transporter-mediated
multidrug and apoptosis resistance in human leukemia stem cell-like
KG-1a cells. Biochem Biophys Res Commun. 394:1098–1104. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Riccioni R, Dupuis ML, Bernabei M, et al:
The cancer stem cell selective inhibitor salinomycin is a
P-glycoprotein inhibitor. Blood Cells Mol Dis. 45:86–92. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ
and Carson DA: Salinomycin inhibits Wnt signaling and selectively
induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl
Acad Sci USA. 108:13253–13257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chergui F, Chretien AS, Bouali S, et al:
Validation of a phosphoprotein array assay for characterization of
human tyrosine kinase receptor downstream signaling in breast
cancer. Clin Chem. 55:1327–1336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martin SJ and Green DR: Apoptosis and
cancer: the failure of controls on cell death and cell survival.
Crit Rev Oncol Hematol. 18:137–153. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reed JC: Apoptosis-targeted therapies for
cancer. Cancer Cell. 3:17–22. 2003. View Article : Google Scholar
|
|
26
|
Schwartz GK and Shah MA: Targeting the
cell cycle: a new approach to cancer therapy. J Clin Oncol.
23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: a review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Katso R, Okkenhaug K, Ahmadi K, White S,
Timms J and Waterfield MD: Cellular function of phosphoinositide
3-kinases: implications for development, homeostasis, and cancer.
Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fraser M, Leung BM, Yan X, Dan HC, Cheng
JQ and Tsang BK: p53 is a determinant of X-linked inhibitor of
apoptosis protein/Akt-mediated chemoresistance in human ovarian
cancer cells. Cancer Res. 63:7081–7088. 2003.PubMed/NCBI
|
|
30
|
Weir NM, Selvendiran K, Kutala VK, et al:
Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant
human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer
Biol Ther. 6:178–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Medema RH, Kops GJ, Bos JL and Burgering
BM: AFX-like Forkhead transcription factors mediate cell-cycle
regulation by Ras and PKB through p27kip1. Nature. 404:782–787.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aggarwal BB: Nuclear factor-kappaB: the
enemy within. Cancer Cell. 6:203–208. 2004.PubMed/NCBI
|
|
34
|
Ono K and Han J: The p38 signal
transduction pathway: activation and function. Cell Signal.
12:1–13. 2000. View Article : Google Scholar
|
|
35
|
Park SJ and Kim IS: The role of p38 MAPK
activation in auranofin-induced apoptosis of human promyelocytic
leukaemia HL-60 cells. Br J Pharmacol. 146:506–513. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bulavin DV and Fornace AJ Jr: p38 MAP
kinase's emerging role as a tumor suppressor. Adv Cancer Res.
92:95–118. 2004.
|
|
38
|
Brozovic A, Fritz G, Christmann M, et al:
Long-term activation of SAPK/JNK, p38 kinase and fas-L expression
by cisplatin is attenuated in human carcinoma cells that acquired
drug resistance. Int J Cancer. 112:974–985. 2004. View Article : Google Scholar : PubMed/NCBI
|
